Oncolytics Biotech, Inc. (ONCY)
0.557
+0.01
(+2.31%)
USD |
NASDAQ |
Oct 09, 16:00
0.5575
0.00 (0.00%)
After-Hours: 20:00
Oncolytics Biotech Cash from Operations (Quarterly) : -8.066M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.066M |
| March 31, 2026 | -7.293M |
| December 31, 2025 | -6.263M |
| September 30, 2025 | -4.896M |
| June 30, 2025 | -4.262M |
| March 31, 2025 | -4.529M |
| December 31, 2024 | -5.198M |
| September 30, 2024 | -3.829M |
| June 30, 2024 | -4.939M |
| March 31, 2024 | -5.511M |
| December 31, 2023 | -4.496M |
| September 30, 2023 | -4.496M |
| June 30, 2023 | -6.303M |
| March 31, 2023 | -5.788M |
| December 31, 2022 | -4.374M |
| September 30, 2022 | -3.252M |
| June 30, 2022 | -5.417M |
| March 31, 2022 | -4.936M |
| December 31, 2021 | -5.026M |
| September 30, 2021 | -2.962M |
| June 30, 2021 | -5.536M |
| March 31, 2021 | -4.398M |
| December 31, 2020 | -4.398M |
| September 30, 2020 | -4.595M |
| June 30, 2020 | -4.517M |
| Date | Value |
|---|---|
| March 31, 2020 | -2.941M |
| December 31, 2019 | -5.496M |
| September 30, 2019 | -3.420M |
| June 30, 2019 | -3.549M |
| March 31, 2019 | -2.547M |
| December 31, 2018 | -3.327M |
| September 30, 2018 | -2.683M |
| June 30, 2018 | 0.4564M |
| March 31, 2018 | -3.644M |
| December 31, 2017 | -2.535M |
| September 30, 2017 | -2.532M |
| June 30, 2017 | -3.383M |
| March 31, 2017 | -2.981M |
| December 31, 2016 | -2.854M |
| September 30, 2016 | -2.318M |
| June 30, 2016 | -2.034M |
| March 31, 2016 | -2.201M |
| December 31, 2015 | -3.229M |
| September 30, 2015 | -2.184M |
| June 30, 2015 | -4.162M |
| March 31, 2015 | -2.214M |
| December 31, 2014 | -2.921M |
| September 30, 2014 | -4.057M |
| June 30, 2014 | -5.30M |
| March 31, 2014 | -5.588M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Sangamo Therapeutics, Inc. | -19.28M |
| Sarepta Therapeutics, Inc. | 197.07M |
| Anixa Biosciences, Inc. | -1.77M |
| Mera Pharmaceuticals, Inc. | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 6.704M |
| Free Cash Flow | -26.53M |
| Free Cash Flow Per Share (Quarterly) | -0.0674 |
| Free Cash Flow to Equity (Quarterly) | -8.006M |
| Free Cash Flow to Firm (Quarterly) | -8.066M |
| Free Cash Flow Yield | -43.17% |